Celltrion reveals Phase 3 clinical trial result of Herzuma at world’s largest oncology conference
Celltrion announced a result of the clinical trials of Herzuma(project name: CT-P6), an antibody biosimilar for the treatment of breast cancer, and Truxima(project name: CT-P10), a biosimilar for the treatment of hematological malignancy, at the American Society of Clinical Oncology in Chicago on...
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.